Breast cancers have diverse characteristics such as their response to treatment and their propensity to relapse. We know that the individual suit of oncogenic lesions probably influences diversity but the characteristics of the cell type from which the cancer arose probably also plays a part. This Application addresses this question and investigates a major new discovery made by the applicant that the ets transcription factor Elf5 plays a key role in specifying the diversity in breast cancer.
The development of protective immunity is essential to fight infection. This depends on a small number of master regulatory transcription factors that drive the differentiation of precursor cells into mature immune cells such as NK, T and dendritic cells. This proposal will provide a fundamental advance in our understanding of immune cells and impact strategies aimed at the prevention and treatment of pathogen infections.
The cell types of the blood, such as red and white blood cells, are produced in the bone marrow from a rare stem cell. The stem cell uses a handful of important master-regulatory genes that act in a hierarchy to promote the blood cell differentiation process. This research aims to understand how these master-regulators function in isolation and together in producing the white blood cells that are required for our immune response to microbes, vaccination and to prevent cancer.
I am a cancer biologist determining the mechanisms controlling growth and proliferation of cancer cells and use transgenic models of malignancy and genetic approaches to identify new therapies for targeting growth control in the treatment of cancer.
Therapeutic Targeting Of Ribosome Biogenesis In Cancer And Ribosomopathies
Funder
National Health and Medical Research Council
Funding Amount
$763,845.00
Summary
My fellowship application will build on my international leadership in understanding growth control in human disease. My vision is to uncover the molecular mechanisms governing the loss of normal control of the synthesis of the molecular machines, termed ribosomes, that are responsible for synthesising all cell proteins. I will translate these findings into new paradigms to treat patients suffering from diseases such as cancer and ribosomopathies, that are associated with ribosome dysfunction.
I am a molecular-cell biologist investigating the genetic control of lymphocyte differentiation. I study the mechanisms of action of transcription factors expressed specifically in B cells that regulate B lymphocyte specialisation and function, that determine the ability of mature B cells to respond to signals from other cells or from invading pathogens, and that enable the differentiation of antibody-secreting cells, the effectors of the B cell lineage. I lead the commercialisation efforts of o ....I am a molecular-cell biologist investigating the genetic control of lymphocyte differentiation. I study the mechanisms of action of transcription factors expressed specifically in B cells that regulate B lymphocyte specialisation and function, that determine the ability of mature B cells to respond to signals from other cells or from invading pathogens, and that enable the differentiation of antibody-secreting cells, the effectors of the B cell lineage. I lead the commercialisation efforts of our research Program.Read moreRead less
Regulation Of The Haemostatic Activity Of Plasma Von Willebrand Factor
Funder
National Health and Medical Research Council
Funding Amount
$851,980.00
Summary
Our genes encode proteins that perform the tasks of life. Most proteins are chemically modified after they are made to control how, when, and where they function. Prof Hogg discovered a new chemical modification of proteins that is important in health and disease. He will apply this discovery to develop new diagnostics and therapies for heart attacks and stroke. Prof Hogg is one of the few Australians to take new diagnostics and therapies developed in the lab to evaluation in patients.
Dr Gilchrist is a reproductive biologist studying factors that regulate the intrinsic quality of unfertilised eggs. He has developed a new form of hormone-free infertility treatment which he will test in a clinical trial over the next 5 years.
My major goal for the past 20 years has been to understand how hormones such as gastrin stimulate the development of gastrointestinal cancer. One approach has been to define the intracellular signalling pathways by which gastrins enhance cell growth. Our discovery that iron is essential for the biological activity of gastrins may allow the development of novel therapies for colon cancer and iron overload.
Molecular Targeting Of Innate Immune Signalling Pathways In Cancer And Auto-Inflammatory Diseases
Funder
National Health and Medical Research Council
Funding Amount
$753,300.00
Summary
To achieve an accurate molecular understanding of innate immune system receptor signalling, both intracellularly and in whole organisms, in health and disease. This knowledge will then be used to generate better treatments for the extensive range of human diseases that are caused or exacerbated by dysfunctional innate immune signalling, including Crohn's disease, psoriasis and cancer.